Journal of Diabetes and its Complications 2010-01-01

Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression ofNɛ-carboxymethyl lysine

Toshihide Kawai, Izumi Takei, Mikiya Tokui, Osamu Funae, Kazunori Miyamoto, Mitsuhisa Tabata, Takumi Hirata, Takao Saruta, Akira Shimada, Hiroshi Itoh

Index: J. Diabetes Complications 24(6) , 424-32, (2010)

Full Text: HTML

Abstract

Objective We investigated the efficacy of epalrestat, an aldose reductase inhibitor, for diabetic peripheral neuropathy in Japanese patients with type 2 diabetes.

Related Compounds

Related Articles:

Inhibitor selectivity between aldo–keto reductase superfamily members AKR1B10 and AKR1B1: Role of Trp112 (Trp111)

2013-11-15

[FEBS Lett. 587(22) , 3681-6, (2013)]

Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase

2009-01-01

[J. Mol. Graph. Model. 28(2) , 162-9, (2009)]

6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.

2010-10-01

[Bioorg. Med. Chem. Lett. 20 , 5630-3, (2010)]

Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts.

2008-09-01

[J. Pharm. Pharmacol. 60(9) , 1227-36, (2008)]

Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

1993-01-01

[Drugs Aging 3(6) , 532-55, (1993)]

More Articles...